Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [ 177 Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer
Theranostics · 2025
DOI: 10.7150/thno.109860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2025. Verfasst von Nathan Poterszman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe, Strasbourg, France. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Heterocyclic Compounds, 1-Ring, Prostate-Specific Antigen, Dipeptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
- Radiopharmacy, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
- Radiophysics, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
- Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
Zitieren
APA
Poterszman, N., Hammer-Lefevre, C., Porot, C., Salvadori, J., Barthélémy, P., & Somme, F. (2025). Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [ 177 Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer. Theranostics. https://doi.org/10.7150/thno.109860
Vancouver
Poterszman N, Hammer-Lefevre C, Porot C, Salvadori J, Barthélémy P, Somme F. Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [ 177 Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer. Theranostics. 2025. doi:10.7150/thno.109860
BibTeX
@article{Poterszman2025,
author = {Poterszman, Nathan and Hammer-Lefevre, Cécile and Porot, Clémence and Salvadori, Julien and Barthélémy, Philippe and Somme, François},
title = {Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [ 177 Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer},
journal = {Theranostics},
year = {2025},
doi = {10.7150/thno.109860}
}
EUVIMED